🇺🇸 FDA
Pipeline program

NBI-98854

NBI-98854-TS2007

Phase 2 small_molecule terminated

Quick answer

NBI-98854 for Tourette Syndrome is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 4 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Tourette Syndrome
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials